Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy

Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy

Evasion of apoptosis is a hallmark of cancer, attributed in part to overexpression of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2). In a variety of cancer types, including lymphoma, Bcl-2 is overexpressed. Therapeutic targeting of Bcl-2 has demonstrated efficacy in the clinic and is the subj...

Full description

Bibliographic Details
Main Authors: Kamila Butowska, Xuexiang Han, Ningqiang Gong, Rakan El-Mayta, Rebecca M. Haley, Lulu Xue, Wenqun Zhong, Wei Guo, Karin Wang, Michael J. Mitchell
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Lipid nanoparticles
Doxorubicin
Bcl-2
siRNA delivery
Chemotherapy
Lymphoma
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383522003239

Internet

http://www.sciencedirect.com/science/article/pii/S2211383522003239

Similar Items